Literature DB >> 19211593

Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling.

A S Magaret1, C Johnston, A Wald.   

Abstract

OBJECTIVES: We evaluated two methods to describe detection of herpes simplex virus (HSV) from the genital mucosa.
METHODS: We assessed genital swabs from HSV-2 seropositive people participating in longitudinal studies of HSV DNA detection at the University of Washington Virology Research Clinic. We determined the length of observation period necessary to ensure some HSV detection for most individuals. We compared two measures to assess differences in shedding according to HIV status, the shedding rate ratio, defined as the proportion of total samples with detectable HSV in HIV-1 seropositive versus HIV-1 seronegative participant, and the ratio of "shedders", defined as the proportion of people with any shedding over the interval in HIV-1 seropositive versus HIV-1 seronegative people.
RESULTS: While only 17% (51/308) of HSV-2 seropositive people shed on their first day on study, 77% (238/308) had some genital shedding over 30 days (any HSV DNA detected on genital swabs). Shedding rate ratios (SRR) for HIV-seropositive versus HIV-seronegative people varied from SRR = 1.42 using 10 samples to SRR = 1.35 using 50 samples. The ratio of "shedders" (RS) approached 1 as the observation period increased (RS = 1.13 using 10 samples to RS = 1.01 using 50 samples). In a hypothetical case, the ratio of "shedders" was shown to exceed 1 when shedding rates were equal.
CONCLUSIONS: Most HSV-2 seropositive people shed HSV from the genital mucosa. Dichotomisation of people into "shedders" and "non-shedders" or "high" and "low" shedders yields inferences that depend upon sampling interval length. Overall shedding rates provide consistent measures regardless of the number of swabs collected.

Entities:  

Mesh:

Year:  2009        PMID: 19211593      PMCID: PMC2730769          DOI: 10.1136/sti.2008.034751

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  29 in total

1.  Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa.

Authors:  Amalia S Magaret; Anna Wald; Meei-Li Huang; Stacy Selke; Larry Corey
Journal:  J Clin Microbiol       Date:  2007-02-28       Impact factor: 5.948

2.  A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.

Authors:  Guy de Bruyn; Mauricio Vargas-Cortez; Terri Warren; Stephen K Tyring; Kenneth H Fife; Jacob Lalezari; Rebecca C Brady; Mohsen Shahmanesh; George Kinghorn; Karl R Beutner; Rajul Patel; Margaret A Drehobl; Patrick Horner; Terrance O Kurtz; Sharon McDermott; Anna Wald; Lawrence Corey
Journal:  Vaccine       Date:  2005-09-21       Impact factor: 3.641

3.  Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.

Authors:  H Nina Kim; Amalia Meier; Meei-Li Huang; Steve Kuntz; Stacy Selke; Connie Celum; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2006-07-12       Impact factor: 5.226

4.  Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.

Authors:  Catherine M Crespi; William G Cumberland; Anna Wald; Lawrence Corey; Sally Blower
Journal:  Sex Transm Infect       Date:  2007-05-02       Impact factor: 3.519

5.  Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.

Authors:  Eileen F Dunne; Sara Whitehead; Maya Sternberg; Sukhon Thepamnuay; Wanna Leelawiwat; Janet M McNicholl; Surin Sumanapun; Jordan W Tappero; Taweesap Siriprapasiri; Lauri Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2008-09-01       Impact factor: 3.731

6.  The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.

Authors:  Rhoda S Sperling; Kenneth H Fife; Terri J Warren; Lynn P Dix; Clare A Brennan
Journal:  Sex Transm Dis       Date:  2008-03       Impact factor: 2.830

7.  Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels.

Authors:  N Nagot; A Ouedraogo; I Konate; H A Weiss; V Foulongne; M C Defer; A Sanon; P Becquart; M Segondy; A Sawadogo; P Van de Perre; P Mayaud
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

8.  Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women.

Authors:  P Mayaud; N Nagot; I Konaté; A Ouedraogo; H A Weiss; V Foulongne; M-C Defer; A Sawadogo; M Segondy; P Van de Perre
Journal:  Sex Transm Infect       Date:  2008-07-02       Impact factor: 3.519

9.  Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples.

Authors:  A J Ryncarz; J Goddard; A Wald; M L Huang; B Roizman; L Corey
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

10.  Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.

Authors:  Nicolas Nagot; Abdoulaye Ouédraogo; Vincent Foulongne; Issouf Konaté; Helen A Weiss; Laurence Vergne; Marie-Christine Defer; Didier Djagbaré; Anselme Sanon; Jean-Baptiste Andonaba; Pierre Becquart; Michel Segondy; Roselyne Vallo; Adrien Sawadogo; Philippe Van de Perre; Philippe Mayaud
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

View more
  19 in total

1.  Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.

Authors:  Ashok Cattamanchi; Misty Saracino; Stacy Selke; Meei-Li Huang; Amalia Magaret; Connie Celum; Lawrence Corey; Anna Wald; Corey Casper
Journal:  J Med Virol       Date:  2011-10       Impact factor: 2.327

2.  Viral kinetics of genital herpes: a molecular probe into host-viral interactions.

Authors:  Thomas C Quinn
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

3.  Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

Authors:  Elfriede Agyemang; Amalia S Magaret; Stacy Selke; Christine Johnston; Larry Corey; Anna Wald
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

4.  Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Authors:  Elizabeth Tronstein; Christine Johnston; Meei-Li Huang; Stacy Selke; Amalia Magaret; Terri Warren; Lawrence Corey; Anna Wald
Journal:  JAMA       Date:  2011-04-13       Impact factor: 56.272

Review 5.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 6.  Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy.

Authors:  Chris L McGowin; Richard B Pyles
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

7.  Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Sharon L Walmsley
Journal:  BMJ Open       Date:  2014-01-24       Impact factor: 2.692

8.  Sample Size for a Binomial Proportion with Autocorrelation.

Authors:  Amalia S Magaret; Jeffrey Stanaway
Journal:  Stat Commun Infect Dis       Date:  2011-10-24

9.  Subclinical Genital Herpes Shedding in HIV/Herpes Simplex Virus 2-Coinfected Women during Antiretroviral Therapy Is Associated with an Increase in HIV Tissue Reservoirs and Potentially Promotes HIV Evolution.

Authors:  Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

10.  High Rate of β-Globin DNA Detection Validates Self-Sampling in Herpes Simplex Virus Shedding Studies.

Authors:  Andrew Mujugira; Meei-Li Huang; Stacy Selke; Linda Drolette; Amalia S Magaret; Anna Wald
Journal:  Sex Transm Dis       Date:  2015-12       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.